InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,505.00
(
-0.71%
)
US TECH 100
19,000.00
(
-0.94%
)
Dow Jones
40,287.53
(
-0.93%
)
Brent Oil
81.88
(
0.00%
)
Bitcoin
67,419.40
(
0.37%
)
Post# of 158400
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

JE2374

Send PM Follow Ignore
Followers 36
Posts 1638
Boards Moderated 0
Alias Born 01/21/2013

JE2374

Re: None

Thursday, 01/31/2013 4:45:29 PM

Thursday, January 31, 2013 4:45:29 PM

Post# of 158400
Comparing Roche and BMSN

ROCHE-RHHBY Obinutuzumab

ZURICH -- Roche Holding AG (ROG.VX) Thursday said the first stage of a phase III study showed Obinutuzumab (GA101) significantly improved progression-free survival in people with chronic lymphocytic leukemia.

BMSN-HemaXellerate

HemaXellerate™ is a cell therapy product developed by Regen BioPharma that uses fat derived from the patient as a source of "healing cells" to stimulate bone marrow production of blood cells. These "healing cells" are termed "endothelial cells" and are a critical component of the blood production machinery of the bone marrow that is damaged in patients with bone marrow failure.

Im no medical expert, but there research and drugs sound very parallel.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up